Drug intelligence / Profile preview

Compound 34

Development stage: Preclinical
Lead developer: Escape Bio
Modality: Small Molecules
Administration: Oral, Intraperitoneal, Subcutaneous, Daily Feed

Overview

"Compound 34" is a generic identifier used across numerous independent research studies to refer to a wide array of distinct chemical entities. These compounds exhibit diverse mechanisms of action and are being investigated for a broad spectrum of potential applications, including various forms of cancer, osteoporosis, Parkinson's disease, spinal cord injury, malaria, fungal infections, bacterial infections, coccidiosis, and pain. Some instances of "Compound 34" are also explored for agricultural uses such as acaricides and herbicides.

Targets

NSD2 (Histone-lysine N-methyltransferase NSD2)

Beyond the preview

Go deeper on Compound 34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 34.

Explore the full profile